|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
GB0230045D0
(en)
|
2002-12-23 |
2003-01-29 |
Glaxo Group Ltd |
Compounds
|
|
JP2006503108A
(ja)
*
|
2002-09-16 |
2006-01-26 |
グラクソ グループ リミテッド |
ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用
|
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
|
AU2004299277A1
(en)
*
|
2003-12-19 |
2005-06-30 |
Glaxo Group Limited |
Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
|
|
GB0405933D0
(en)
*
|
2004-03-16 |
2004-04-21 |
Glaxo Group Ltd |
Compounds
|
|
US20080275078A1
(en)
*
|
2004-03-16 |
2008-11-06 |
Glaxo Group Limited |
Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
|
|
WO2005118543A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Ono Pharmaceutical Co., Ltd. |
キナーゼ阻害薬およびその用途
|
|
EP1841780B1
(en)
|
2005-01-10 |
2011-07-27 |
Glaxo Group Limited |
Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
|
|
AU2006255028B2
(en)
|
2005-06-06 |
2012-04-19 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
CN101243080A
(zh)
*
|
2005-06-27 |
2008-08-13 |
阿姆布里利亚生物制药公司 |
作为hiv整合酶抑制剂的吡唑并[3，4-b]吡啶-2-基]-苯甲酸衍生物
|
|
US20090221644A1
(en)
*
|
2005-06-30 |
2009-09-03 |
Stuart Edward Bradley |
Gpcr Agonists
|
|
US20090325924A1
(en)
*
|
2005-06-30 |
2009-12-31 |
Stuart Edward |
GPCR Agonists
|
|
EP1931668A2
(en)
|
2005-09-16 |
2008-06-18 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
|
|
WO2007031838A1
(en)
|
2005-09-16 |
2007-03-22 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
US20090131431A1
(en)
*
|
2005-09-29 |
2009-05-21 |
Christopher David Edlin |
Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
|
|
PE20071068A1
(es)
|
2005-12-20 |
2007-12-13 |
Glaxo Group Ltd |
Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
|
|
WO2007103308A2
(en)
*
|
2006-03-07 |
2007-09-13 |
Array Biopharma Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
|
MX2008013411A
(es)
|
2006-04-20 |
2008-11-04 |
Glaxo Group Ltd |
Nuevos compuestos.
|
|
JP5440934B2
(ja)
|
2006-05-24 |
2014-03-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
置換プテリジン
|
|
KR20090042227A
(ko)
|
2006-06-06 |
2009-04-29 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
|
CL2007001829A1
(es)
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
|
GB0614570D0
(en)
*
|
2006-07-21 |
2006-08-30 |
Glaxo Group Ltd |
Compounds
|
|
PL2046787T3
(pl)
|
2006-08-01 |
2011-10-31 |
Glaxo Group Ltd |
Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
|
|
US8492378B2
(en)
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
|
WO2008070095A1
(en)
|
2006-12-05 |
2008-06-12 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
|
NZ579645A
(en)
*
|
2007-03-14 |
2012-01-12 |
Ranbaxy Lab Ltd |
Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
|
|
US20110130403A1
(en)
*
|
2007-03-14 |
2011-06-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
|
|
PE20081889A1
(es)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
Indol carboxamidas como inhibidores de ikk2
|
|
BRPI0817211A2
(pt)
|
2007-09-20 |
2017-05-16 |
Irm Llc |
composto composições como moduladores da atividade de gpr119
|
|
US8080546B2
(en)
|
2007-10-26 |
2011-12-20 |
Amgen Inc. |
Pyrazolo-pyridinone derivatives and methods of use
|
|
EP2240028B1
(en)
*
|
2007-12-06 |
2016-07-20 |
Intra-Cellular Therapies, Inc. |
Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
|
|
AR070562A1
(es)
|
2008-02-06 |
2010-04-21 |
Glaxo Group Ltd |
Farmacoforos duales - antagonistas muscarinicos de pde4
|
|
UY31636A1
(es)
|
2008-02-06 |
2009-08-03 |
|
Farmacoforos duales-antagonistas muscarinicos de pde4
|
|
WO2009100169A1
(en)
*
|
2008-02-06 |
2009-08-13 |
Glaxo Group Limited |
Dual pharmacophores - pde4-muscarinic antagonistics
|
|
PE20091553A1
(es)
*
|
2008-02-06 |
2009-10-30 |
Glaxo Group Ltd |
Farmacoforos duales - antagonistas muscarinicos de pde4
|
|
EP2249830A4
(en)
*
|
2008-02-06 |
2012-07-18 |
Glaxo Group Ltd |
DUAL PHARMACOPHORES, ANTAGONISTS OF MUSCARINIC RECEPTORS AND INHIBITORS OF PDE4 ACTIVITY
|
|
EP2100599A1
(en)
*
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
MX2010012814A
(es)
|
2008-05-23 |
2010-12-20 |
Amira Pharmaceuticals Inc |
Inhibidor de proteina activadora de 5-lipoxigenasa.
|
|
US8163743B2
(en)
|
2008-06-05 |
2012-04-24 |
GlaxoGroupLimited |
4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
|
|
JP5438103B2
(ja)
*
|
2008-07-02 |
2014-03-12 |
アモーレパシフィック コーポレイション |
バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
|
|
EP2346867A1
(en)
*
|
2008-09-19 |
2011-07-27 |
Ranbaxy Laboratories Limited |
Phosphodiestarase inhibitors
|
|
MA32942B1
(fr)
|
2008-12-06 |
2012-01-02 |
Intra Cellular Therapies Inc |
Composes organiques
|
|
JP5778582B2
(ja)
|
2008-12-06 |
2015-09-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． |
有機化合物
|
|
EP2367430B1
(en)
|
2008-12-06 |
2014-08-13 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
EP2367431B1
(en)
|
2008-12-06 |
2015-08-05 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
KR20110103949A
(ko)
*
|
2008-12-06 |
2011-09-21 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
|
BRPI0922809A2
(pt)
|
2008-12-06 |
2018-05-29 |
Intracellular Therapies Inc |
compostos orgânicos
|
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
|
EP2414292B1
(en)
|
2009-02-24 |
2017-09-06 |
Boydel Investments Group Inc. |
Wastewater treatment apparatus and method
|
|
JP5656880B2
(ja)
|
2009-03-09 |
2015-01-21 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
|
|
WO2010102968A1
(en)
|
2009-03-10 |
2010-09-16 |
Glaxo Group Limited |
Indole derivatives as ikk2 inhibitors
|
|
EP2408769A1
(en)
|
2009-03-17 |
2012-01-25 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
|
JP2012520684A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
EP2408916A2
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2408458A1
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
|
JP2012521760A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
WO2010111471A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2411520A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2411018A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
|
WO2010111497A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2421834A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
|
AR076373A1
(es)
|
2009-04-24 |
2011-06-08 |
Glaxo Group Ltd |
N-pirazolil carboxamidas como inhibidores de canales de calcio
|
|
LT2899191T
(lt)
|
2009-04-30 |
2017-10-25 |
Glaxo Group Limited |
Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
|
|
JP2012526810A
(ja)
|
2009-05-13 |
2012-11-01 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
|
WO2011067364A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Novel compounds
|
|
JP2013512880A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
|
|
WO2011067365A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of p13 kinases
|
|
KR20120123325A
(ko)
*
|
2009-12-15 |
2012-11-08 |
시오노기세야쿠 가부시키가이샤 |
혈관 내피 리파아제 저해 활성을 갖는 옥사디아졸 유도체
|
|
WO2011107394A1
(en)
|
2010-03-01 |
2011-09-09 |
Glaxo Group Limited |
Treatment of anxiety disorders
|
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
|
TW201209054A
(en)
|
2010-05-28 |
2012-03-01 |
Prosidion Ltd |
Novel compounds
|
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
|
WO2011153135A1
(en)
|
2010-05-31 |
2011-12-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
EP2576551A4
(en)
|
2010-05-31 |
2014-04-16 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
|
WO2011153136A1
(en)
|
2010-05-31 |
2011-12-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
RS54286B1
(sr)
|
2010-09-08 |
2016-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
|
|
US9326987B2
(en)
|
2010-09-08 |
2016-05-03 |
Glaxo Group Limited |
Indazole derivatives for use in the treatment of influenza virus infection
|
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
|
EP2630127A1
(en)
|
2010-10-21 |
2013-08-28 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
|
US9156791B2
(en)
|
2010-10-21 |
2015-10-13 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, immune and inflammatory conditions
|
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
|
EP2683716A1
(en)
|
2011-03-11 |
2014-01-15 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
|
JP6051210B2
(ja)
|
2011-06-10 |
2016-12-27 |
イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． |
有機化合物
|
|
WO2013117693A1
(en)
|
2012-02-10 |
2013-08-15 |
Glaxosmithkline Intellectual Property Development Limited |
Pde4 inhibitor for treating huntington's disease
|
|
NZ631258A
(en)
|
2012-04-25 |
2016-11-25 |
Takeda Pharmaceuticals Co |
Nitrogenated heterocyclic compound
|
|
WO2014010732A1
(ja)
|
2012-07-13 |
2014-01-16 |
武田薬品工業株式会社 |
複素環化合物
|
|
US9801882B2
(en)
|
2013-02-17 |
2017-10-31 |
Intra-Cellular Therapies, Inc. |
Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
|
|
EP2975031A4
(en)
|
2013-03-14 |
2017-04-19 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
EP2968338B1
(en)
|
2013-03-15 |
2019-01-09 |
Intra-Cellular Therapies, Inc. |
Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
|
|
KR102240326B1
(ko)
|
2013-03-15 |
2021-04-13 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
|
EP3018123B1
(en)
|
2013-07-03 |
2023-05-10 |
Takeda Pharmaceutical Company Limited |
Amide compound
|
|
JP6427491B2
(ja)
|
2013-07-03 |
2018-11-21 |
武田薬品工業株式会社 |
複素環化合物
|
|
JPWO2015012328A1
(ja)
|
2013-07-24 |
2017-03-02 |
武田薬品工業株式会社 |
複素環化合物
|
|
RU2016112268A
(ru)
|
2013-10-17 |
2017-11-22 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Ингибитор PI3K для лечения респираторного заболевания
|
|
WO2015055691A1
(en)
|
2013-10-17 |
2015-04-23 |
Glaxosmithkline Intellectual Property Development Limited |
Pi3k inhibitor for treatment of respiratory disease
|
|
US20170100385A1
(en)
|
2014-05-12 |
2017-04-13 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pharmaceutical compositions comprising danirixin for treating infectious diseases
|
|
EP3157926B1
(en)
|
2014-06-20 |
2019-05-15 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
|
US10131671B2
(en)
|
2014-08-07 |
2018-11-20 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
CA2961212C
(en)
|
2014-09-17 |
2024-02-06 |
Intra-Cellular Therapies, Inc. |
Compounds and methods
|
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
US10682354B2
(en)
|
2016-03-28 |
2020-06-16 |
Intra-Cellular Therapies, Inc. |
Compositions and methods
|
|
US10034861B2
(en)
|
2016-07-04 |
2018-07-31 |
H. Lundbeck A/S |
1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
|
|
US20190161480A1
(en)
|
2016-08-08 |
2019-05-30 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical Compounds
|
|
JP7134168B6
(ja)
|
2016-09-12 |
2024-02-02 |
イントラ－セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
DK3717488T3
(da)
*
|
2017-11-27 |
2021-12-13 |
Dart Neuroscience Llc |
Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
|
|
EP3723807B1
(en)
*
|
2017-12-14 |
2021-10-20 |
H. Lundbeck A/S |
Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
|
|
AR113926A1
(es)
|
2017-12-14 |
2020-07-01 |
H Lundbeck As |
Derivados de 1h-pirazolo[4,3-b]piridinas
|
|
US10766893B2
(en)
*
|
2017-12-20 |
2020-09-08 |
H. Lundbeck A/S |
1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
|
|
WO2019121840A1
(en)
|
2017-12-20 |
2019-06-27 |
H. Lundbeck A/S |
Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
|
|
CA3087841A1
(en)
|
2018-01-12 |
2019-07-18 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
|
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ－セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
|
EP4413980A3
(en)
|
2019-09-03 |
2024-10-30 |
Intra-Cellular Therapies, Inc. |
Novel compounds
|
|
US12364695B2
(en)
|
2020-06-02 |
2025-07-22 |
Intra-Cellular Therapies, Inc. |
Methods of treating inflammatory disease
|
|
WO2023049199A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Zeno Management, Inc. |
Azole compounds
|
|
JPWO2024143336A1
(https=)
*
|
2022-12-28 |
2024-07-04 |
|
|